Sterling Capital Management’s Dianthus Therapeutics DNTH Stock Holding History

Sterling Capital Management’s Portfolio DNTH Stock Details DNTH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$137K	Buy	1,561 +1,395	+840%	+$145K	﹤0.01%	1288
2026 Q2	$16.2K	Sell	166 -939	-85%	-$82K	﹤0.01%	1980
2026 Q1	$92.7K	Sell	1,105 -192	-15%	-$11.1K	﹤0.01%	1417
2025 Q4	$53.4K	Buy	1,297 +258	+25%	+$10K	﹤0.01%	1777
2025 Q3	$40.9K	Buy	1,039 +553	+114%	+$14.1K	﹤0.01%	1832
2025 Q2	$9.05K	Buy	486 +102	+27%	+$1.91K	﹤0.01%	2190
2025 Q1	$6.97K	Sell	384 -327	-46%	-$7.21K	﹤0.01%	2001
2024 Q4	$15.5K	Buy	711 +633	+812%	+$16.3K	﹤0.01%	1958
2024 Q3	$2.14K	Buy	+78	New	+$2.17K	﹤0.01%	2155

Other funds holding DNTH

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $103B AUM 40.17% 1-Year Est. Return

Pictet Asset Management Carouge, Switzerland $106B AUM 32.76% 1-Year Est. Return

Barclays London, United Kingdom $500B AUM 36.84% 1-Year Est. Return

Fisher Asset Management Camas, Washington $348B AUM 26.9% 1-Year Est. Return

Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return

Emerald Advisers Leola, Pennsylvania $3.64B AUM 71.19% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return

Candriam SCA Strassen, Luxembourg, Luxembourg $22.5B AUM 50.38% 1-Year Est. Return

TimesSquare Capital Management New York $6.12B AUM 30.01% 1-Year Est. Return

Sterling Capital Management's DNTH Position: Q3 2026 in Review

Sterling Capital Management increased its Dianthus Therapeutics (DNTH) stake by 840% in Q3 2026, buying an estimated $145K and bringing the position to 1,561 shares worth $137K. The position accounts for ﹤0.01% of the portfolio, ranked #1288.

Sterling Capital Management first reported a position in DNTH in Q3 2024 and has held it in 9 quarters since. 87 funds tracked by Wall St. Rank hold DNTH as of Q3 2026.

Sterling Capital Management held 1,561 shares of Dianthus Therapeutics worth $137K as of Q3 2026.
Sterling Capital Management bought 1,395 Dianthus Therapeutics shares in Q3 2026, an estimated $145K.
Dianthus Therapeutics made up ﹤0.01% of Sterling Capital Management's portfolio in Q3 2026, its #1288 holding.
Sterling Capital Management first reported a position in Dianthus Therapeutics in Q3 2024 and has held it in 9 quarters since.
87 funds tracked by Wall St. Rank held Dianthus Therapeutics as of Q3 2026.

Based on Sterling Capital Management's 13F filing for Q3 2026, filed 22 Oct 2026.